Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 12, 2007, Pages 2587-2593

  Hwang, E Shelley ^a,e   Miglioretti, Diana L ^b   Ballard Barbash, Rachel ^c   Weaver, Donald L ^d   Kerlikowske, Karla ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMA IN SITU; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; TUMOR REGRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 38849095121     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0458     Document Type: Article

References (46)

1. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 1997;22:151-6.
2. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-54.
3. Breast Cancer Facts and Figures 2005-2006. American Cancer Society 2005.
4. Radford DM, Phillips NJ, Fair KL, Ritter JH, Holt M, Donis-Keller H, Allelic loss and the progression of breast cancer. Cancer Res 1995;55:5180-3.
5. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
6. Hwang ES, DeVries S, Chew KL, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004;10:5160-7.
7. Lee LA, Silverstein MJ, Chung CT, et al. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma- in-situ of the breast. Am J Surg 2006;192:416-9.
8. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 1996;56:5260-5.
9. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982;50:1309-14.
10. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-4.
11. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005;103:1778-84.
12. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003;95:1692-702.
13. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-52.
14. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24randomi sed controlled trial. Lancet 1999;353:1993-2000.
15. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-61.
16. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006;24:1031-6.
17. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
18. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic densities and breast cancer risk. Breast Dis 1998;10:113-26.
19. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
20. Warner E, Lockwood G, Tritchler D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1992;16:67-72.
21. Titus-Ernstoff L, Tosteson AN, Kasales C, et al. Breast cancer risk factors in relation to breast density (United States). Cancer Causes Control 2006;17:1281-90.
22. Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002;347:886-94 .
23. Vachon CM, Sellers TA, Vierkant RA, Wu FF, Brandt KR. Case-control study of increased mammographic breast density response to hormone replacement therapy. Cancer Epidemiol Biomarkers Prev 2002;11:1382-8.
24. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density: a hormonally responsive risk factor for breast cancer. J Br Menopause Soc 2006;12:186-93.
25. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
26. Irwin ML, Aiello EJ, McTiernan A, et al. Physical activity, body mass index, and mammographic density in postmenopausal breast cancer survivors. J Clin Oncol 2007;25:1061-6.
27. Boyd NF, Greenberg C, Lockwood, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89:488-96.
28. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
29. Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol 1997;169:1001-8.
30. Sickles EA, Miglioretti DL, Ballard-Barbash R, et al. Performance benchmarks for diagnostic mammography. Radiology 2005;235:775-90.
31. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-95.
32. Lin DY, Shen L, Ying Z, Breslow NE. Group sequential designs for monitoring survival probabilities. Biometrics 1996;52:1033-41.
33. Habel LA, Dignam JJ, Land SR, Salane M, Capra AM, Julian TB. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst 2004;96:1467-72.
34. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40:IV-43-8.
35. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40:IV-49-54.
36. Sumner WE III, Koniaris LG, Snell SE, et al. Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol 2007;14:1638-43.
37. Ursin G, Pike MC, Spicer DV, Porrath SA, Reitherman RW. Can mammographic densities predict effects of tamoxifen on the breast? J Natl Cancer Inst 1996;88:128-9.
38. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-5.
39. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000;9:917-21.
40. Vachon CM, Ingle JN, Suman VJ, et al. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 2007;16:204-10.
41. Gill JK, Maskarinec G, Pagano I, Kolonel LN. The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res 2006;8:R30.
42. Reinier KS, Vacek PM, Geller BM. Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Breast Cancer Res Treat 2007;10:343-8.
43. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328:1581-6.
44. Lahmann PH, Schulz M, Hoffmann K, et al. Long-term weight change and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Br J Cancer 2005;93:582-9.
45. Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2005;14:656-61.
46. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193-201.